Page last updated: 2024-12-11

trandolapril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5484727
CHEMBL ID1519
CHEBI ID9649
SCHEMBL ID16610
MeSH IDM0147889

Synonyms (97)

Synonym
BIDD:GT0804
AKOS015843316
udrik
ru-44570
preran
odric
odrik
gopten
mavik
(2s,3ar,7as)-1-(n-((1s)-1-((ethyloxy)carbonyl)-3-phenylpropyl)-l-alanyl)octahydro-1h-indole-2-carboxylic acid
ru 44570
1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1h-indol-2-carboxylic acid
(2s,3ar,7as)-1-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
ccris 6594
trandolaprilum [latin]
1h-indole-2-carboxylic acid, 1-((2s)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s,3ar,7as)-
1h-indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-alpha,7a-beta))-
trandolapril
DB00519
mavik (tn)
87679-37-6
D00383
trandolapril (jan/usp/inn)
NCGC00095153-01
NCGC00182079-03
nsc-758939
CHEMBL1519
(2s,3ar,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2s)-1-[(2r)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
A842336
(2s,3ar,7as)-1-[(2s)-2-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
NCGC00182079-02
HMS3262J10
tox21_113152
cas-87679-37-6
tox21_111453
dtxcid003692
dtxsid2023692 ,
bdbm50369775
trandolapril [usp:inn:ban]
hsdb 8392
1t0n3g9crc ,
unii-1t0n3g9crc
trandolaprilum
nsc 758939
LP00924
trandolapril [who-dd]
trandolapril component of tarka
trandolapril [orange book]
(2s,3ar,7as)-1-[(s)-n-[(s)-1-carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
trandolapril [ep monograph]
1h-indole-2-carboxylic acid, octahydro n-((2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-1-alanyl (2s,3ar,7as)
trandolapril [usp monograph]
trandolapril [usp-rs]
trandolapril [vandf]
tarka component trandolapril
trandolapril [mart.]
trandolapril [inn]
trandolapril [jan]
trandolapril [mi]
AKOS015896050
S6468
gtpl6453
CCG-222228
HY-B0592
SCHEMBL16610
VXFJYXUZANRPDJ-WTNASJBWSA-N
tox21_500924
NCGC00261609-01
(2s,3ar,7as)-1-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl)octahydro-1h-indole-2-carboxylic acid
(2s,3ar,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1h-indole-2-carboxylic acid
sr-02000000917
SR-02000000917-2
trandolapril, united states pharmacopeia (usp) reference standard
CHEBI:9649 ,
trandolapril, >=98% (hplc), white powder
trandolapril, european pharmacopoeia (ep) reference standard
trandolapril; (2s,3ar,7as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydro-1h-indole-2-carboxylic acid
trandolapril/(2s,3ar,7as)-1-[(2s)-2-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid
KS-1467
Q929420
BRD-K28550399-001-01-4
(2s,3ar,7as)-1-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
SDCCGSBI-0633768.P001
W18796
2s,3ar,7as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic acid, mavik
trandolapril (usp-rs)
trandolapril tablets
trandolaprilum (latin)
(2s,3ar,7as)-1-((s)-n-((s)-1-ethoxycarbonyl-3-phenylpropyl)alanyl)hexahydro-2-indoline carboxylic acid
c09aa10
trandolapril (usp monograph)
(2s,3ar,7as)-1-((2s)-2-(((2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
trandolapril (usp:inn:ban)
trandolapril (ep monograph)
trandolapril (mart.)
EN300-7481395

Research Excerpts

Overview

Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor. It is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction.

ExcerptReferenceRelevance
"Trandolapril is a centrally active ACE inhibitor."( Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration.
Hariharan, A; Jagtap, AG; Shetty, S; Shirole, T, 2014
)
1.12
"Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. "( Update on the use of trandolapril in the management of cardiovascular disorders.
Diaz, A; Ducharme, A, 2008
)
2.11
"Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or symptoms of chronic heart failure within the first 2 days after an acute myocardial infarction (AMI). "( Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Guay, DR, 2003
)
3.2
"Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension."( Efficacy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population.
Adiga, S; Bairy, KL; Jayaprakash, B; Naidu, MU; Nair, S; Rao, D; Shankar, PK; Shashikiran, U; Usha Rani, P; Vidyasagar, S,
)
1.14
"Trandolapril is a non-sulfhydryl prodrug which, after oral administration, is hydrolysed in the liver to its active diacid, trandolaprilat. "( Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.
McTavish, D; Wiseman, LR, 1994
)
3.17
"Trandolapril is a prodrug that is rapidly hydrolyzed to its active diacid metabolite, trandolaprilat."( Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group.
Gray, JM; Paster, R; Saunders, E; Weir, MR, 1995
)
1.22
"Trandolapril (RU44570) is an ethyl ester prodrug of trandolprilat (RU44403) having angiotensin I-converting enzyme (ACE) inhibitory activity. "( Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hasegawa, Y; Hirayama, M; Kurihara, A; Manabe, T,
)
1.57
"Trandolapril is a newly developed angiotensin-converting enzyme (ACE) inhibitor that is rapidly hydrolyzed mainly in the liver to its biologically active metabolite trandolaprilat. "( Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor.
Brunner, HR; Conen, H, 1993
)
2.03
"Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. "( Trandolapril: a clinical profile.
de Leeuw, PW, 1995
)
3.18
"Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of patients with hypertension and congestive heart failure (CHF), and after myocardial infarction (MI). "( Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Noble, S; Peters, DC; Plosker, GL, 1998
)
3.19
"Trandolapril is a newly developed angiotensin converting enzyme inhibitor (ACEI) whose characteristic is that it undergoes hepatic excretion. "( [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
Fukuda, M; Morozumi, K; Takeda, A; Toda, S; Yoshida, A, 2000
)
2.07
"Trandolapril is a new angiotensin-converting enzyme (ACE) inhibitor that has been extensively investigated in vitro, in animals, in normal volunteers, and in hypertensive patients. "( Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor.
Brunner, HR; Duc, LN, 1992
)
3.17

Effects

Trandolapril has a favourable pharmacological profile and an antihypertensive efficacy at least comparable to that of other ACE inhibitors. The drug has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment.

Trandolapril has demonstrated potent ACE inhibition, a long plasma half-life and a high degree of lipophilicity. It has no sharp peak in its zero-order spectrum and therefore, it is difficult to be measured by direct spectrophotometry. TrandolAPril has a sufficient duration of inhibition of plasma ACE activity to allow once-daily dosing.

ExcerptReferenceRelevance
"Trandolapril has a sufficient duration of inhibition of plasma ACE activity to allow once-daily dosing. "( Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Guay, DR, 2003
)
3.2
"Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment."( Trandolapril: a clinical profile.
de Leeuw, PW, 1995
)
2.46
"trandolapril has a favourable pharmacological profile and an antihypertensive efficacy at least comparable to that of other ACE inhibitors. "( Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Noble, S; Peters, DC; Plosker, GL, 1998
)
3.19
"4. Trandolapril has an anti-ischaemic effect."( Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril.
Bachetti, T; Bernocchi, P; Cargnoni, A; Ceconi, C; Comini, L; Curello, S; Ferrari, R, 2001
)
1.07
"Trandolapril has no sharp peak in its zero-order spectrum and therefore, it is difficult to be measured by direct spectrophotometry. "( Univariate calibrations with or without chemometric assistance for determination of drugs lacking peak maxima in their zero-order profiles.
Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2019
)
1.96
"Trandolapril has demonstrated potent ACE inhibition, a long plasma half-life and a high degree of lipophilicity."( Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study.
Coca, A; Rabasseda, X, 2003
)
2.48
"Trandolapril has a sufficient duration of inhibition of plasma ACE activity to allow once-daily dosing. "( Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Guay, DR, 2003
)
3.2
"Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment."( Trandolapril: a clinical profile.
de Leeuw, PW, 1995
)
2.46
"Trandolapril has similar antihypertensive efficacy to enalapril as indicated by several clinical trials."( Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Noble, S; Peters, DC; Plosker, GL, 1998
)
2.46
"trandolapril has a favourable pharmacological profile and an antihypertensive efficacy at least comparable to that of other ACE inhibitors. "( Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Noble, S; Peters, DC; Plosker, GL, 1998
)
3.19
"4. Trandolapril has an anti-ischaemic effect."( Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril.
Bachetti, T; Bernocchi, P; Cargnoni, A; Ceconi, C; Comini, L; Curello, S; Ferrari, R, 2001
)
1.07

Actions

ExcerptReferenceRelevance
"Trandolapril reduced all-cause mortality, with a relative risk reduction associated with trandolapril treatment of 0.78 (p = 0.0013)."( Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Carlsen, J; Køber, L; Torp-Pedersen, C, 1996
)
1.25

Treatment

Treatment with trandolapril attenuated the reduction in aortic flow and cardiac output index and the increase in left ventricular end-diastolic pressure. It also improved the developed force transients of the skinned fibre of the animal with CHF without causing a reduction of infarct size.

ExcerptReferenceRelevance
"Trandolapril treatment reduced systemic blood pressure and lessened proteinuria after RMR, as well as expression of TGF-beta1, endoglin and collagens."( Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction.
Arévalo, M; Düwel, A; Eleno, N; López-Novoa, JM; Morales, AI; Pérez-Barriocanal, F; Prieto, M; Rivas, JV; Rodríguez-Peña, A; Sánchez, RJ, 2005
)
1.32
"Trandolapril treatment decreased the Ang II and Phe potencies in carotid arteries, but did not affect the maximal response."( B(2)-receptor modulation of the reactivity to phenylephrine and angiotensin II in the carotid artery of normotensive rats after trandolapril treatment.
Accorsi-Mendonça, D; Corrêa, FM; Oliveira, AM, 2006
)
1.26
"Trandolapril treatment significantly reduced MMP-9 and MMP-2 activities to 68.5% and 53.2%, respectively."( Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats.
Furubayashi, K; Inoue, N; Jin, D; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Miyazaki, M; Takai, S; Tanaka, H, 2007
)
1.31
"Trandolapril treatment resulted in 15% diminution in blood pressure (BP)."( Regression of left ventricular hypertrophy by converting enzyme inhibition in 12-15-month-old spontaneously hypertensive rats: effects on coronary resistance and ventricular compliance in normoxia and anoxia.
Amrani, FC; Cheaw, SL; Chevalier, B; Hamon, G; Jouquey, S; Paolaggi, F; Swynghedauw, B, 1994
)
1.01
"When trandolapril treatments (placebo or with indomethacin) were compared to treatments without trandolapril (placebo or indomethacin), trandolapril lowered clinic SBP by 5.4 mm Hg (P = 0.047) and DBP by 2.3 mm Hg (P = 0.08)."( Indomethacin does not attenuate the hypotensive effect of trandolapril.
Lyons, D; MacDonald, TM; Petrie, JC; Pritchard, G; Webster, J, 1996
)
0.99
"Trandolapril treatment was associated with a significant (P < 0.04) increase in the AUC1-12 of t-PA antigen in the ID group compared with that of the placebo-treated ID group, whereas PAI-1 antigen concentration did not differ between the groups."( Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Billaud, E; Gram, J; Jespersen, J; Jeunemaitre, X; Pedersen, OD, 1997
)
1.02
"Trandolapril treatment prevented the development of hypertension."( Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy.
Arévalo, M; Flores, O; Gallego, B; Hidalgo, F; López-Novoa, JM; Vidal, S,
)
0.85
"Trandolapril treatment resulted in an increase in the active renin and decrease in the urinary kallikrein activity in both study groups."( Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension.
Angelova-Gateva, P; Baurenski, L; Nachev, E; Orbetzova, M; Torbova, S; Tzingilev, D; Vergilova, J; Wippermann, M; Zacharieva, S, 1998
)
2.46
"Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well."( Update on the use of trandolapril in the management of cardiovascular disorders.
Diaz, A; Ducharme, A, 2008
)
1
"Treatment with trandolapril reversed the augmented contractile response of the rat with CHF to norepinephrine, prostaglandin F2 alpha, and angiotensin II almost to the levels in the sham-operated rat."( Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure.
Nasa, Y; Okumura, Y; Sanbe, A; Takeo, S; Toga, W, 1996
)
0.91
"Treatment with trandolapril (0.05 mg/kg) plus verapamil (0.1 mg/kg) inhibited this vasoconstriction in response to repeated hypoxia."( Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
Kirchengast, M, 1997
)
0.87
"Treatment with trandolapril resulted in a relative risk of death from any cause for the hypertensive group of 0.59 (96% confidence interval 0.44-0.80), versus 0.85 (0.72-1.02) for normotensive patients."( Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event.
Gustafsson, F; Hildebrandt, P; Køber, L; Torp-Pedersen, C, 1997
)
0.84
"Treatment with trandolapril attenuated the reduction in aortic flow and cardiac output index and the increase in left ventricular end-diastolic pressure, and improved the developed force transients of the skinned fibre of the animal with CHF without causing a reduction of infarct size."( Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction.
Sanbe, A; Takeo, S; Yamaguchi, F, 1998
)
0.91
"Treatment with trandolapril in the hypertensive individuals was associated with a reduction in the relative risk of death to 0.59 (95% confidence interval 0.44-0.80), versus 0.85 (0.72-1.02) in the normotensive individuals."( Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study.
Gustafsson, F; Køber, L; Torp-Pedersen, C, 1998
)
0.83
"Treatment with trandolapril prolonged the running time, reversed the rates of decrease in ATP and CP and the rate of increase in lactate, and restored the Ca-ATPase activity (51.11+/-0.56 micromol Pi mg(-1) protein h(-1), n = 7; P<0.05) and composition ratio of MHC isoforms in the gracilis muscle."( Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril.
Fujimoto, Y; Gen, E; Igarashi, T; Kamano, I; Kawana, K; Maki, T; Nasa, Y; Sanbe, A; Takeo, S; Tanonaka, K; Yamaguchi, F, 1999
)
0.86
"Treatment with trandolapril resulted in a relative risk (RR) of death from any cause for the diabetic group of 0.64 (95% confidence interval 0.45 to 0.91) versus 0.82 (0.69 to 0.97) for the nondiabetic group."( Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.
Gustafsson, F; Gustafsson, I; Hildebrandt, P; Køber, L; Torp-Pedersen, C, 1999
)
0.89

Toxicity

Adverse events, possibly related to drug, were more common with nifedipine SR (34%) than with trandolapril (17%; p < 0.1) Withdrawals owing to adverse events were three from trandlapril and eight from the captopril group.

ExcerptReferenceRelevance
" Assessment criteria included evaluation of plasma ACE and renin activity and aldosterone levels in the supine and standing positions, monitoring of blood pressure, heart rate and electrocardiogram, routine blood and urine laboratory tests, and evaluation of adverse effects."( Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers.
Bianco, L; Caravaggi, M; Crema, A; D'Angelo, L; De Ponti, F; Frigo, GM; Lecchini, S; Marelli, C, 1991
)
0.55
" No serious adverse effect was encountered."( Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor.
Granier, J; Le Go, A; Patat, A; Surjus, A, 1989
)
0.54
" Withdrawals owing to adverse events were three from trandolapril and eight from the captopril group."( Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group.
Pauly, NC; Safar, ME, 1994
)
0.8
" The incidence of adverse events was similar in all three groups."( Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group.
Meyer, BH; Pauly, NC, 1994
)
0.54
" However, at least as important is a consideration of adverse reactions and the safety of the combination compared to monotherapy."( Safety profile of the combination of verapamil and trandolapril.
Holzgreve, H, 1997
)
0.55
"In randomized placebo-controlled studies adverse events were observed in 25."( Safety profile of the combination of verapamil and trandolapril.
Holzgreve, H, 1997
)
0.55
"In summary, the profile of adverse drug reactions of a fixed-dose combination of verapamil and trandolapril consists the typical side effects of the monocompounds."( Safety profile of the combination of verapamil and trandolapril.
Holzgreve, H, 1997
)
0.77
"The aim of the present study was to investigate the incidence of adverse effects and the prognostic value of various risk factors in a large population of unselected hypertensive patients treated with the ACE inhibitor trandolapril."( [Risk factors of adverse effects of angiotensin-converting enzyme inhibitors. Apropos of 30,072 patients treated by trandolapril].
Chambrelan, F; Dutrey-Dupagne, C; Elkik, F; Genès, N; Pochoy, A; Rauss, A; Vaur, L,
)
0.53
" In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug."( [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999
)
0.3
" Adverse events and safety were also evaluated."( Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.
Andrup, M; Karlberg, BE; Odén, A, 2000
)
0.55
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In spite of the low dose ingested, the postmortem cardiac blood verapamil level was clearly toxic (6000 ng/mL, or 6 mg/L)."( Verapamil toxicity: an unusual case report and review of the literature.
Batalis, NI; Harley, RA; Schandl, CA, 2007
)
0.34
"The presence of hyponatremia has been perceived to increase the risk of adverse events on initiation of treatment with angiotensin-converting enzyme inhibition in heart failure patients."( Efficacy and safety of angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Balling, L; Gustafsson, F; Kober, L; Schou, M; Torp-Pedersen, C, 2013
)
0.39

Pharmacokinetics

Trandolaprilat inhibits the angiotensin converting enzyme (ACE) and displays similar pharmacodynamic properties to other ACE inhibitors. It improves haemodynamic and cardiac parameters in patients with essential hypertension. The concomitant administration of trandolAPril did not affect the pharmacodynamic effects of warfarin.

ExcerptReferenceRelevance
" Trandolaprilat inhibits the angiotensin converting enzyme (ACE) and displays similar pharmacodynamic properties to other ACE inhibitors, improving haemodynamic and cardiac parameters in patients with essential hypertension."( Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.
McTavish, D; Wiseman, LR, 1994
)
2.64
" The peak plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were slightly higher in the older group, but the elimination half-life (t1/2) was the same, with no accumulation after repeat dosing."( Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension.
Arner, P; Bryce, T; Engfeldt, P; Lenfant, B; Mouren, M; Stepniewski, JP; Sultan, E; Wade, A, 1994
)
0.55
"1 mg/kg RU44403 was not dose proportional, suggesting nonlinear pharmacokinetic profile."( Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hasegawa, Y; Hirayama, M; Kurihara, A; Manabe, T,
)
0.13
" The maximum plasma concentration of trandolaprilat, and the area under the concentration curve (0-96 h) correlated inversely with creatinine clearance (r = -0."( Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
Aldigier, JC; Bevan, EG; Conte, JJ; Grunfeld, JP; Harper, SJ; McInnes, GT; Meyer, BH; Pauly, N; Wilkinson, R, 1993
)
0.79
"The concomitant administration of trandolapril did not affect the pharmacodynamic effects of warfarin."( Multiple doses of trandolapril do not affect warfarin pharmacodynamics.
Badenhorst, PN; de la Rey, N; Luus, HG; Meyer, BH; Müller, FO, 1995
)
0.9

Compound-Compound Interactions

The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on SAM levels in hypertensive type-2 diabetic patients.

ExcerptReferenceRelevance
"The efficacy and safety of trandolapril alone and in combination with a calcium channel blocker were evaluated in 13,147 hypertensive patients over 60 years old."( [Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age].
Destrée, D; Dutrey-Dupagne, C; Elkik, F; Genes, N; Gosse, P; Vaur, L, 1995
)
0.94
"To evaluate the clinical efficacy and safety of a new antihypertensive drug combination of trandolapril/verapamil compared to monotherapy with verapamil or trandolapril, in patients with mild to moderate primary hypertension."( Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.
Andrup, M; Karlberg, BE; Odén, A, 2000
)
0.77
"The new fixed drug combination trandolapril/verapamil was superior to monotherapy with either of these drugs alone regarding reduction of both BP and rate pressure product."( Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.
Andrup, M; Karlberg, BE; Odén, A, 2000
)
0.84
" The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on SAM levels in hypertensive type-2 diabetic patients."( The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes.
Escalante-Acosta, BA; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2008
)
0.96
"The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients."( Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension.
Castro-Serna, D; Escalante-Acosta, BA; Rodríguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2011
)
1.02
" Untreated ACF TGR exhibited marked impairment of renal function and the treatment with ACEi alone or combined with sEH inhibition did not prevent it."( Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Červenka, L; Hammock, BD; Hwang, SH; Imig, JD; Kala, P; Kopkan, L; Melenovský, V; Nishiyama, A; Sadowski, J; Sedláková, L; Škaroupková, P; Táborský, M; Vaňourková, Z, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Increased nitric oxide bioavailability can only partially explain the reduced platelet activation by eplerenone and ACE inhibition."( Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
Bauersachs, J; Christ, M; Eigenthaler, M; Fraccarollo, D; Hildemann, S; Kobsar, A; Schäfer, A; Walter, U, 2003
)
0.32
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction.
Kandikere, VN; Mudigonda, K; Nirogi, RV; Shrivastava, W, 2006
)
0.67
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The combination doses tested showed a sustained and marked antihypertensive effect throughout the 24-hour dosing interval. Clear dose-response curves were observed for trandolapril from 0 to 2 mg.

ExcerptRelevanceReference
"In this study the dose-response curves reflecting the arterial and the antihypertensive effects of converting enzyme inhibition were analysed."( Converting enzyme inhibition: dissociation between antihypertensive and arterial effects.
Asmar, RG; Benetos, A; Darne, BM; Pauly, NC; Safar, ME, 1992
)
0.28
" In conclusion, trandolapril is an effective, well-tolerated antihypertensive agent for once-daily dosing at either 1 or 2 mg."( Effects of trandolapril on 24-h ambulatory blood pressure in patients with mild-to-moderate essential hypertension.
Ambrosoli, L; Belcaro, G; Cesarone, MR; De Sanctis, MT; Laurora, G; Marelli, C, 1994
)
1.02
"A double blind randomised comparison of two angiotensin-converting enzyme (ACE) inhibitors was made in a study in which ambulatory blood pressure was monitored over a steady-state dosage interval and the subsequent 24-h period, the latter being designed to mimic a missed dose of drug."( Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients.
Boussac, J; Bouvier d'Yvoire, M; Dutrey-Dupagne, C; Elkik, F; Genes, N; Meredith, PA; Vaur, L, 1995
)
0.56
" Two additional recordings were done successively on days 50 and 51 corresponding to a normal dosing day and a following day with a simulated missed dose, respectively."( [Duration of action of trandolapril in mild to moderate hypertensive patients evaluated by ambulatory measurement of blood pressure].
Breton, C; Chevrier, J; Courvoisier, A; D'Hotel, R; Diesel, J; Dutrey-Dupagne, C; Kownator, S; Schaaf, R; Vaur, L,
)
0.44
" Orally dosed RU44403 was scarcely absorbed from the gastrointestinal tract (3% of dose), whereas its prodrug was found to be rapidly absorbed (32."( Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hasegawa, Y; Hirayama, M; Kurihara, A; Manabe, T,
)
0.13
" After a double-blind treatment of 4 weeks with either of the dosage regimens, patients were then crossed over to the alternate regimen for the last 4 weeks of the study."( Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate essential hypertension: assessment by conventional and ambulatory blood pressures.
Bourgeois, J; Lacourcière, Y; Poirier, L, 1993
)
0.68
"A teratogenicity study was performed in Sprague-Dawley rats treated orally with trandolapril (RU44570) at the dosage levels of 3, 30 and 300 mg/kg/day from day 7 to day 17 of pregnancy."( [Teratological study of trandolapril (RU44570) in rats].
Hiramatsu, Y; Kumagai, Y; Kurio, W; Maeda, H; Matsuura, T; Narama, I; Takabatake, E, 1993
)
0.82
"A perinatal and postnatal study was performed in female Sprague-Dawley rats treated orally with trandolapril (RU44570) at dosage levels of 3, 30 and 300 mg/kg/day from day 17 of pregnancy to postpartum day 21."( [Perinatal and postnatal study of trandolapril (RU44570) in rats].
Fujishima, H; Hiramatsu, Y; Kumagai, Y; Kurio, W; Matsuura, T; Narama, I; Takabatake, E, 1993
)
0.78
"A fertility study was performed in Sprague-Dawley rats treated orally with trandolapril (RU44570) at the dosage levels of 3, 30 and 300 mg/kg/day."( [Fertility study of trandolapril (RU44570) in rats].
Fujishima, H; Hiramatsu, Y; Kumagai, Y; Kurio, W; Matsuura, T; Narama, I; Takabatake, E, 1993
)
0.84
" Trandolapril was continued for another 4 weeks in responding patient, otherwise the dosage of trandolapril was doubled or another antihypertensive was added."( [Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age].
Destrée, D; Dutrey-Dupagne, C; Elkik, F; Genes, N; Gosse, P; Vaur, L, 1995
)
1.55
"Once-daily antihypertensive drugs that control blood pressure (BP) for the full 24-h dosing period, enhance patient compliance and may reduce the cardiovascular complications of hypertension which occur with increased frequency in the early morning."( Once-daily monotherapy with trandolapril in the treatment of hypertension.
Black, HR; Neutel, JM; Schoenberger, JA; Smith, DH; Weber, MA, 1996
)
0.59
" The 24-h therapeutic coverage was assessed by the morning to evening BP decrease ratio (M/E ratio) which represents the ratio of the trough effect to the 12-h post dosing efficacy."( Assessment of drug efficacy using home self-blood pressure measurement: the SMART study. Self Measurement for the Assessment of the Response to Trandolapril.
Chatellier, G; Dutrey-Dupagne, C; Elkik, F; Genès, N; Ménard, J; Vaur, L; Zannad, F, 1996
)
0.49
" Doubling of the dosage was authorized after the first four weeks when the DBP remained higher than 90 mmHg with a fall in DBP < 10 mmHg."( [Efficacy and tolerability of trandolapril in overweight hypertensive patients].
Bensaïd, J; Maarek, M, 1996
)
0.58
" In contrast, the single dosing of all agents failed to show antinociceptive effect."( Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice.
Miyazaki, M; Okunishi, H; Song, K; Takai, S; Tanaka, T, 1996
)
0.29
" It is concluded that the combination doses tested showed a sustained and marked antihypertensive effect throughout the 24-hour dosing interval, and the starting dose (verapamil 180 mg plus trandolapril 2 mg) seems appropriate in this group of patients."( Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment.
Hlatswayo, Z; Radevski, I; Sareli, P; Skoularigis, J; Strugo, V, 1997
)
0.74
" After a 4-week single-blind placebo phase, patients received one of the following daily dosage regimens in a double-blind fashion for 6 weeks: placebo, 4 mg of trandolapril, 240 mg of verapamil SR, or a combination of 4 mg of trandolapril and 240 mg of verapamil SR."( Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.
Elliott, WJ; Frishman, WH; Messerli, F, 1998
)
0.8
"To investigate the dose-response relationship and contribution of verapamil SR and trandolapril given in combination once a day for the treatment of essential hypertension."( Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group.
Compagnone, D; Scholze, J; Zilles, P, 1998
)
0.86
"All dosage combinations of verapamil SR and trandolapril produced significantly greater reduction of blood pressure than the monotherapy at the same dosage."( Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group.
Compagnone, D; Scholze, J; Zilles, P, 1998
)
0.9
" The main compliance parameters were the percentage of missed doses, the percentage of delayed doses, and the percentage of correct dosing periods."( Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial.
Elkik, F; Genes, N; Legrand, C; Poggi, L; Vaisse, B; Vaur, L, 1999
)
0.3
" The percentage of correct dosing periods, ie, a period with only one correct recorded opening, was 94."( Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen.
Andrejak, M; Carré, A; Clerson, P; Genes, N; Poncelet, P; Vaur, L, 2000
)
0.31
" Verapamil SR/trandolapril 180/2 mg combination produces the best dose-response ratio of different dose combinations of these two drugs."( The fixed combination of verapamil SR/trandolapril.
Widimský, J, 2000
)
0.94
"Trandolapril was given to male Wistar rats with aortic banding at 10 AM or 10 PM for 6 weeks to examine the influence of dosing time on the development of left ventricular mass (LVM)."( Dosing time-dependent effect of trandolapril on the prevention of cardiac hypertrophy in rats with aortic banding.
Fujimura, A; Kawaguchi, A; Ohmori, M; Sugimoto, K; Tsuruoka, S, 2001
)
2.04
" In the former patients, a once-daily dosage of trandolapril has produced significant and long-lasting reductions in blood pressure and has reduced left ventricular hypertrophy."( Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study.
Coca, A; Rabasseda, X, 2003
)
2.02
" Genuine dose-response studies on combination therapy are not available and published studies involved adding one drug on top of 'usual treatment'."( Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction.
Bie, P; Christensen, NJ; Dalgaard, P; Frandsen, EK; Galløe, AM; Larsen, K; Nielsen, SL; Skagen, K, 2006
)
0.33
" To achieve BP target a combination of antihypertensives will be needed, and the use of long-acting drugs that are able to provide 24-hour efficacy with a once-daily dosing confers the noteworthy advantages of compliance improvement and BP variation lessening."( Trandolapril/verapamil combination in hypertensive diabetic patients.
García Donaire, JA; Ruilope, LM, 2007
)
1.78
" This may explain some of the beneficial effects of this fixed dosed combination that are non-related to its antihypertensive effects."( The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes.
Escalante-Acosta, BA; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2008
)
0.71
" Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration."( Update on the use of trandolapril in the management of cardiovascular disorders.
Diaz, A; Ducharme, A, 2008
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
organic heterobicyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.52050.000229.305416,493.5996AID743069
arylsulfatase AHomo sapiens (human)Potency0.67461.069113.955137.9330AID720538
flap endonuclease 1Homo sapiens (human)Potency0.16830.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.00090.00010.533610.0000AID39767
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (92)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345457Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))1994Journal of cardiovascular pharmacology, , Volume: 23 Suppl 4Compared properties of trandolapril, enalapril, and their diacid metabolites.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1476471Half life in human liver microsomes at 10 uM up to 120 mins by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1476469Half life in rat liver microsomes at 1 uM up to 120 mins by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39767Inhibitory activity against angiotensin I converting enzyme (ACE)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (511)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (1.57)18.7374
1990's192 (37.57)18.2507
2000's233 (45.60)29.6817
2010's64 (12.52)24.3611
2020's14 (2.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.22 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index6.19 (4.65)
Search Engine Demand Index111.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials214 (39.56%)5.53%
Reviews54 (9.98%)6.00%
Case Studies18 (3.33%)4.05%
Observational1 (0.18%)0.25%
Other254 (46.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healt [NCT01164800]Phase 152 participants (Actual)Interventional2006-03-31Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Trandolapril 4 mg Tablets Versus Mavik® 4 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects [NCT00840632]Phase 140 participants (Actual)Interventional2004-10-31Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healt [NCT01164787]Phase 152 participants (Actual)Interventional2006-03-31Completed
Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives [NCT00679653]Phase 3171 participants (Actual)Interventional2002-02-28Completed
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Trandolapril 4 mg Tablets Under Fed Conditions. [NCT00840073]Phase 150 participants (Actual)Interventional2004-10-31Completed
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]Phase 4252 participants (Actual)Interventional2006-10-31Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]Phase 310,000 participants (Anticipated)Interventional2016-04-11Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]Phase 42,400 participants (Anticipated)Interventional2016-02-29Recruiting
A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension [NCT00235001]Phase 4120 participants (Actual)Interventional2004-06-30Completed
A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL) [NCT00233532]Phase 42,000 participants (Actual)Interventional2004-03-31Completed
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy [NCT00234871]Phase 4357 participants (Actual)Interventional2004-01-31Completed
INternational VErapamil SR Trandolapril STudy [NCT00133692]Phase 422,000 participants Interventional1997-09-30Completed
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome [NCT00234858]Phase 4280 participants (Actual)Interventional2004-03-31Completed
A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) [NCT00235014]Phase 41,204 participants (Actual)Interventional1997-03-31Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]Phase 4291 participants (Actual)Interventional2015-06-01Completed
Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS) [NCT00252317]Phase 464 participants (Anticipated)Interventional2005-11-30Recruiting
Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients? [NCT01437371]Phase 335 participants (Actual)Interventional2011-08-31Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Metabolic Effects of Antihypertensive Drugs [NCT00887510]Phase 424 participants (Actual)Interventional2007-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00391846 (8) [back to overview]Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]Discontinuations
NCT00391846 (8) [back to overview]Number of CV Deaths
NCT00391846 (8) [back to overview]Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00840073 (5) [back to overview]AUC0-72 - Trandolaprilat
NCT00840073 (5) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00840073 (5) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00840073 (5) [back to overview]Cmax - Maximum Observed Concentration
NCT00840073 (5) [back to overview]Cmax - Trandolaprilat
NCT00840632 (6) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00840632 (6) [back to overview]AUC0-inf - Trandolaprilat
NCT00840632 (6) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00840632 (6) [back to overview]AUC0-t - Trandolaprilat
NCT00840632 (6) [back to overview]Cmax - Maximum Observed Concentration
NCT00840632 (6) [back to overview]Cmax - Trandolaprilat
NCT00887510 (2) [back to overview]Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After Addition of HCTZ to Trandolapril
NCT00887510 (2) [back to overview]Change in Total Adiponectin Level After Addition of Trandolapril to HCTZ Compared With Change in Adiponectin After Addition of HCTZ to Trandolapril
NCT01669434 (6) [back to overview]Acute Renal Failure
NCT01669434 (6) [back to overview]Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]Number of Participants With Interoperative Hypotension
NCT01669434 (6) [back to overview]Older Age Subgroup
NCT01669434 (6) [back to overview]Postoperative Hypertension
NCT01669434 (6) [back to overview]Postoperative Hypotension
[back to top]

Changes in Heart Failure Symptoms

Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status. (NCT00391846)
Timeframe: 9 months and baseline

InterventionCategorial scale (Mean)
Guided by NT-proBNP3.67
Not Guided by NT-proBNP6.11

[back to top]

Changes in NT-proBNP Values Over Time in All Patients

The 95% confidential interval (CI) is given as measure of dispersion (NCT00391846)
Timeframe: 9 months and baseline

Interventionng/L (Geometric Mean)
Guided by NT-proBNP2332.1
Not Guided by NT-proBNP2063

[back to top]

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented (NCT00391846)
Timeframe: 9 months

InterventionScores on a scale (Mean)
Guided by NT-proBNP118.6
Not Guided by NT-proBNP128.4

[back to top]

Discontinuations

Number of patients discontinued due to adverse events' (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP8
Not Guided by NT-proBNP6

[back to top]

Number of CV Deaths

Number of deaths (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP4
Not Guided by NT-proBNP5

[back to top]

Number of Days in Hospital for CV Reason

Each overnight stay is counted as one day. The lower the better (NCT00391846)
Timeframe: 9 months

InterventionDays in hospital (Mean)
Guided by NT-proBNP5.79
Not Guided by NT-proBNP5.94

[back to top]

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm. (NCT00391846)
Timeframe: 9 months

InterventionTitration steps (Number)
Guided by NT-proBNP517
Not Guided by NT-proBNP485

[back to top]

AUC0-72 - Trandolaprilat

Informational Purposes Only (NCT00840073)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Trandolapril127.6059
Mavik®123.4560

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf (NCT00840073)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Trandolapril7.0104
Mavik®7.9967

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t (NCT00840073)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Trandolapril6.9056
Mavik®6.7143

[back to top]

Cmax - Maximum Observed Concentration

Bioequivalence based on Cmax (NCT00840073)
Timeframe: Blood samples collected over 72 hour period

Interventionng/mL (Mean)
Trandolapril5.2604
Mavik®5.4938

[back to top]

Cmax - Trandolaprilat

Informational Purposes Only (NCT00840073)
Timeframe: Blood samples collected over 72 hour period

Interventionng/mL (Mean)
Trandolapril6.9610
Mavik®6.6815

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf (NCT00840632)
Timeframe: Blood samples collected over 24 hour period

Interventionpg*h/mL (Mean)
Trandolapril4868.37
Mavik®4826.71

[back to top]

AUC0-inf - Trandolaprilat

Informational Purposes Only (NCT00840632)
Timeframe: Blood samples collected over 72 hour period

Interventionpg*h/mL (Mean)
Trandolapril138305.28
Mavik®138925.03

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t (NCT00840632)
Timeframe: Blood samples collected over 24 hour period

Interventionpg*h/mL (Mean)
Trandolapril4609.82
Mavik®4612.53

[back to top]

AUC0-t - Trandolaprilat

Informational Purposes Only (NCT00840632)
Timeframe: Blood samples collected over 72 hour period

Interventionpg*h/mL (Mean)
Trandolapril111204.01
Mavik®111685.36

[back to top]

Cmax - Maximum Observed Concentration

Bioequivalence based on Cmax (NCT00840632)
Timeframe: Blood samples collected over 24 hour period

Interventionpg/mL (Mean)
Trandolapril4559.54
Mavik®4872.59

[back to top]

Cmax - Trandolaprilat

Informational Purposes Only (NCT00840632)
Timeframe: Blood samples collected over 72 hour period

Interventionpg/mL (Mean)
Trandolapril6682.74
Mavik®6526.16

[back to top]

Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After Addition of HCTZ to Trandolapril

Comparing the change in OGTT AUC rand 1 visit4-visit 3 with rand 2 visit 3-2. This allows for understanding the effects of addition of trandolapril to 12 weeks of HCTZ compared with addition of HCTZ to 12 weeks of trandolapril. This is the primary outcome of the study. (NCT00887510)
Timeframe: OGTT AUC measured over 120 minutes after receiving study intervention for 18-24 weeks.

Interventionminutes*mg/dl (Mean)
Thiazide First-472
Trandolapril First1571

[back to top]

Change in Total Adiponectin Level After Addition of Trandolapril to HCTZ Compared With Change in Adiponectin After Addition of HCTZ to Trandolapril

"Comparing the change in adiponectin: rand 1 visit4-visit 3 with rand 2 visit 3-2.~This allows for understanding the effects of addition of trandolapril to 12 weeks of HCTZ compared with addition of HCTZ to 12 weeks of trandolapril." (NCT00887510)
Timeframe: Over the course of 18 weeks

Interventionmcg/ml (Mean)
Thiazide First-1.36
Trandolapril First0.42

[back to top]

Acute Renal Failure

Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level (NCT01669434)
Timeframe: Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission6
ACEI Continuation10

[back to top]

Low Blood Pressure Subgroup

Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg. (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission4
ACEI Continuation2

[back to top]

Number of Participants With Interoperative Hypotension

Number of Participants with Interoperative Hypotension (systolic blood pressure under 80 mmHg) (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission76
ACEI Continuation95

[back to top]

Older Age Subgroup

Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission48
ACEI Continuation49

[back to top]

Postoperative Hypertension

Any systolic blood pressure greater than 180 mmHg. (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission33
ACEI Continuation17

[back to top]

Postoperative Hypotension

Any systolic blood pressure less than 90 mmHg (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission15
ACEI Continuation31

[back to top]